{"id":"https://openalex.org/W2006830353","doi":"https://doi.org/10.1159/000362558","title":"Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up","display_name":"Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up","alternate_titles":[],"publication_year":2014,"publication_date":"2014-04-04","ids":{"openalex":"https://openalex.org/W2006830353","doi":"https://doi.org/10.1159/000362558","mag":"2006830353","pmid":"https://pubmed.ncbi.nlm.nih.gov/24714208"},"language":"en","primary_location":{"id":"doi:10.1159/000362558","doi":"https://doi.org/10.1159/000362558","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000362558","pdf_url":null,"source":{"id":"https://openalex.org/S84102376","display_name":"Neuroendocrinology","issn_l":"0028-3835","issn":["0028-3835","1423-0194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2006830353"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086752045","display_name":"Murali Kesavan","orcid":"https://orcid.org/0000-0001-8080-6749","observed_orcids":["https://orcid.org/0000-0001-8080-6749"]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]},{"id":"https://openalex.org/I2802692842","display_name":"Fremantle Hospital","ror":"https://ror.org/03yxgmm62","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2800882159","https://openalex.org/I2802692842","https://openalex.org/I4388446375","https://openalex.org/I4388482742"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Murali Kesavan","raw_affiliation_strings":["Department of Hematology, Fremantle Hospital, The University of Western Australia, Fremantle, W.A., Australia","Hematology,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Fremantle Hospital, The University of Western Australia, Fremantle, W.A., Australia","institution_ids":["https://openalex.org/I177877127","https://openalex.org/I2802692842"]},{"raw_affiliation_string":"Hematology,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108471798","display_name":"Phillip G. Claringbold","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Phillip G. Claringbold","raw_affiliation_strings":["Oncology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050960969","display_name":"J. Harvey Turner","orcid":"https://orcid.org/0000-0002-5254-9914","observed_orcids":["https://orcid.org/0000-0002-5254-9914"]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]},{"id":"https://openalex.org/I2802692842","display_name":"Fremantle Hospital","ror":"https://ror.org/03yxgmm62","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2800882159","https://openalex.org/I2802692842","https://openalex.org/I4388446375","https://openalex.org/I4388482742"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Harvey Turner","raw_affiliation_strings":["Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Fremantle, W.A., Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Fremantle, W.A., Australia","institution_ids":["https://openalex.org/I177877127","https://openalex.org/I2802692842"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.3932,"has_fulltext":false,"cited_by_count":89,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.93606232,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"99","issue":"2","first_page":"108","last_page":"117"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12505","display_name":"Peptidase Inhibition and Analysis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/177lu-octreotate","display_name":"177Lu-octreotate","score":0.9020000100135803},{"id":"https://openalex.org/keywords/peptide-receptor-radionuclide-therapy","display_name":"peptide receptor radionuclide therapy","score":0.9890000224113464},{"id":"https://openalex.org/keywords/gastroenteropancreatic-neuroendocrine-tumors","display_name":"gastroenteropancreatic neuroendocrine tumors","score":0.968999981880188},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.9490000009536743},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.8500000238418579},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9150000214576721},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9089999794960022},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9139999747276306},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.9570000171661377},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.996999979019165},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.8960000276565552}],"concepts":[{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.8835163116455078},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7629051208496094},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7143319249153137},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.647179365158081},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.610701322555542},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.594976007938385},{"id":"https://openalex.org/C2779066768","wikidata":"https://www.wikidata.org/wiki/Q1981276","display_name":"Neuroendocrine tumors","level":2,"score":0.549528956413269},{"id":"https://openalex.org/C2993559085","wikidata":"https://www.wikidata.org/wiki/Q2126444","display_name":"Radionuclide therapy","level":2,"score":0.543080747127533},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5249500274658203},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.5212781429290771},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5106995701789856},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.23232713341712952},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077204","descriptor_name":"Temozolomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001792","descriptor_name":"Blood Platelets","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001792","descriptor_name":"Blood Platelets","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004067","descriptor_name":"Digestive System Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006402","descriptor_name":"Hematologic Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D006402","descriptor_name":"Hematologic Diseases","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006402","descriptor_name":"Hematologic Diseases","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007414","descriptor_name":"Intestinal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009504","descriptor_name":"Neutrophils","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009504","descriptor_name":"Neutrophils","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013274","descriptor_name":"Stomach Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013921","descriptor_name":"Thrombocytopenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D013921","descriptor_name":"Thrombocytopenia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D013921","descriptor_name":"Thrombocytopenia","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1159/000362558","doi":"https://doi.org/10.1159/000362558","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000362558","pdf_url":null,"source":{"id":"https://openalex.org/S84102376","display_name":"Neuroendocrinology","issn_l":"0028-3835","issn":["0028-3835","1423-0194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:publications/312f6a0e-2e43-4338-928c-11e6631f651c","doi":null,"is_oa":false,"landing_page_url":"https://research-repository.uwa.edu.au/en/publications/312f6a0e-2e43-4338-928c-11e6631f651c","pdf_url":null,"source":{"id":"https://openalex.org/S4306402492","display_name":"UWA Profiles and Research Repository (UWA)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177877127","host_organization_name":"The University of Western Australia","host_organization_lineage":["https://openalex.org/I177877127"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kesavan, M, Claringbold, P G & Turner, J H 2014, 'Hematological toxicity of combined 177lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up', Neuroendocrinology, vol. 99, no. 2, pp. 108-117. https://doi.org/10.1159/000362558","raw_type":"info:eu-repo/semantics/article"},{"id":"pmid:24714208","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24714208","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1964586919","https://openalex.org/W1988986189","https://openalex.org/W2002814858","https://openalex.org/W2009629472","https://openalex.org/W2012856564","https://openalex.org/W2064560087","https://openalex.org/W2090232354","https://openalex.org/W2098132980","https://openalex.org/W2105649247","https://openalex.org/W2108613323","https://openalex.org/W2115686439","https://openalex.org/W2125398839","https://openalex.org/W2137142564","https://openalex.org/W2148881212","https://openalex.org/W2148933046","https://openalex.org/W2158474413"],"related_works":["https://openalex.org/W3163719982","https://openalex.org/W2469875234","https://openalex.org/W1982090431","https://openalex.org/W2098132980","https://openalex.org/W4220688048","https://openalex.org/W2128544796","https://openalex.org/W2945884344","https://openalex.org/W2743184713","https://openalex.org/W2028793063","https://openalex.org/W2125398839"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,166,214,239],"combination":[2,44,264],"of":[3,14,35,70,89,136,144,161,168,187,201,208,244,246,256,275],"radiopeptide":[4,276],"therapy":[5,9],"[peptide":[6],"receptor":[7],"radionuclide":[8],"(PRRT)]":[10],"with":[11,40,45,86,103,139,259,265],"radiosensitizing":[12,257],"chemotherapy":[13,258],"gastroenteropancreatic":[15],"neuroendocrine":[16],"tumors":[17],"(GEP":[18],"NETs)":[19],"may":[20],"improve":[21],"efficacy,":[22],"but":[23,225],"has":[24,268],"the":[25,66,133,202,209,254,269,273],"potential":[26,270],"to":[27,52,271],"increase":[28],"myelotoxicity.":[29],"In":[30],"a":[31,50,53,116,158,185],"prospective":[32],"clinical":[33],"study":[34],"GEP":[36,79,247],"NET":[37],"patients":[38,83,137,146,176,203,210,231],"treated":[39,85,138],"(177)Lu-octreotate":[41,140],"PRRT":[42,245],"in":[43,81,128,132,174,195,199,206,232,263],"capecitabine":[46,95,102,260],"and":[47,68,99,110,141,152,197,204,218,220,261],"temozolomide,":[48],"as":[49],"prelude":[51],"planned":[54],"Australasian":[55],"Gastro-Intestinal":[56],"Trials":[57],"Group":[58],"(AGITG)":[59],"international":[60],"randomized":[61],"controlled":[62],"trial,":[63],"we":[64],"characterized":[65],"incidence":[67,167],"degree":[69],"hematological":[71,113,122,242],"toxicity.":[72],"MATERIALS":[73],"AND":[74],"METHODS:":[75],"Well-differentiated":[76],"progressive":[77],"metastatic":[78],"NETs":[80,248],"65":[82],"were":[84],"4":[87],"cycles":[88],"7.8":[90],"GBq":[91],"(177)Lu-octreotate,":[92,266],"1,650":[93],"mg/m(2)":[94,101,105],"(n":[96,107,211],"=":[97,108,212],"28)":[98],"1,500":[100],"200":[104],"temozolomide":[106,262],"37),":[109],"monitored":[111],"for":[112,184],"toxicity":[114,123,243],"over":[115,157],"5-year":[117],"period.":[118],"RESULTS:":[119],"Short-term,":[120],"self-limited":[121],"grade":[124,170],"3/4":[125,171],"comprised":[126],"anemia":[127,151,205],"1":[129],"patient":[130],"(3.5%)":[131,147,156],"28":[134],"patient-cohort":[135],"capecitabine.":[142],"One":[143],"these":[145],"later":[148],"developed":[149,154,235],"significant":[150,193],"one":[153],"thrombocytopenia":[155,194],"median":[159,186,216],"follow-up":[160,183],"60":[162],"months":[163,189],"(SD":[164,190],"20).":[165],"short-term":[169],"reversible":[172,241],"myelosuppression":[173],"37":[175],"after":[177],"(177)Lu-octreotate/capecitabine/temozolomide":[178],"was":[179],"zero.":[180],"Long-":[181],"term":[182],"36":[188],"11)":[191],"showed":[192],"2.7%":[196,200],"neutropenia":[198],"10.8%":[207],"4).":[213],"3-year":[215],"hemoglobin":[217],"platelet":[219],"neutrophil":[221],"counts":[222],"trended":[223],"downwards,":[224],"remained":[226],"within":[227],"normal":[228],"ranges.":[229],"Two":[230],"this":[233],"cohort":[234],"myelodysplastic":[236],"syndrome.":[237],"CONCLUSION:":[238],"modest":[240],"is":[249],"not":[250],"significantly":[251],"increased":[252],"by":[253],"addition":[255],"which":[267],"enhance":[272],"efficacy":[274],"therapy.":[277]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2006830353","counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
